IL6 and atherosclerosis: For the monoclonal antibody ziltivekimab, directed against IL-6, in 2 clinicalphase 2 studies: RESCUE (in patients from the USA) [52] and RESCUE-2 [53] (inpatients from Japan) demonstrated the effectiveness in reducing inflammatory andthrombotic markers of atherosclerosis in patients with chronic kidney disease, athigh risk of developing atherosclerosis.